Clarivate Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple myeloma patient populations, covering 171 countries and…
Clarivate Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss due to the targeting of anagen hair follicles by the host immune system. The primary…
Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of schizophrenia for…
Clarivate Epidemiology’s coverage of IgA nephropathy (IgAN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
In June 2021, Biogen / Eisai’s anti-Aβ MAb Aduhelm received accelerated approval from the FDA for the treatment of Alzheimer’s disease (AD), making it the first potential DMT approved for this…
Clarivate Epidemiology’s coverage of hidradenitis suppurativa (HS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Prostate Cancer
Clarivate Epidemiology’s coverage of acute lymphoblastic leukemia (ALL) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…